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Abstract
Minors entering treatment for alcohol and other drug (AOD) use disorders tend to smoke at high 
rates, and many have comorbid attention deficit hyperactivity disorder (ADHD). Clear-air laws 
force patients to refrain from smoking on the premises of AOD treatment facilities, which may 
hinder the progress of treatment-seeking populations who smoke and struggle with ADHD 
comorbidity in particular. This study explores clinical characteristics associated with smoking 
among youths presenting for residential treatment, clinical characteristics associated with smoking 
cessation, and the impact of smoking cessation with ADHD comorbidity on AOD treatment 
response. Participants were 195 adolescents (52% female, aged 14–18 years) court-referred to 
residential treatment. Data were collected at intake, prospectively each week for the 10-week 
treatment period, and at discharge. Two-thirds (67%) of the enrollment sample entered treatment 
smoking half a pack a day on average, a large proportion (50%) of which did not smoke during 
treatment. ADHD patients were more likely to smoke before and during treatment except for those 
who got active in service and step-work. Quitting smoking did not adversely affect AOD outcomes 
and was associated with better prognosis of lowered AOD cravings for youths with and without 
ADHD. Smoking cessation during adolescent AOD treatment is recommended with provision of 
pharmaceutical and/or behavioral modalities that reduce nicotine withdrawal.
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1. Introduction
Tobacco use is the number one preventable cause of disease, disability, and death in the 
United States (CDC, 2010a). Some populations are more at risk of tobacco use disorders 
than others. Whereas approximately one out of every four Americans smokes, three out of 
four individuals with alcohol and other drug (AOD) use disorders are smokers (Bobo & 
Husten, 2000; Grant, Hasin, Chou, Stinson, & Dawson, 2004). Furthermore, smoking is 
more likely to kill patients than the AOD problems for which they sought treatment (Hser, 
McCarthy, & Anglin, 1994; Hurt et al., 1996). Neuropsychiatric disorders characterized by 
impaired cognition and impulsivity such as attention deficit hyperactivity disorder (ADHD) 
also increase the risk of tobacco use disorders; smoking rates are twice as high among 
individuals with ADHD than the general population or controls without ADHD (Kollins, 
McClernon, & Fuemmeler, 2005). Minors are also disproportionately vulnerable to tobacco 
use disorders; tobacco use frequently starts in adolescence, and 80 percent of teen initiators 
continue to smoke into adulthood, curtailing lung growth, brain development, and longevity 
(CDC, 2010b; DiFranza et al., 2002; Kandel & Chen, 2000). The risk of tobacco use 
disorders and associated medical comorbidity is compounded for substance dependent 
youths with ADHD (Biederman et al., 2006).
The last few decades have witnessed an explosion of pharmacological aids in the treatment 
of nicotine dependence, alcohol and drug addiction, and ADHD, including: 1) nicotine 
replacement therapies (NRTs) to aid smoking quit attempts (American Cancer Society, 
2015); 2) naltrexone and acamprosate to reduce the reinforcing qualities of alcohol (Bouza, 
Magro, Muñoz, & Amate, 2004); 3) suboxone and methadone replacement 
pharmacotherapies for the treatment of narcotic use disorders (Miller, Wilbourne, & 
Hettema, 2003); and 4) stimulants for the treatment of ADHD. ADHD pharmacotherapies, 
in particular, have demonstrated large effects (d = 0.80) in reducing ADHD symptoms and in 
preventing addiction among young adults (Jain, Jain, & Islam, 2011; Lambert & Hartsough, 
1998).
1.1. Treatment
Despite these biomedical advances, associated benefits do not reach populations who suffer 
the most with all three conditions, and minors in particular. Co-existing tobacco-use 
disorders are often inadequately addressed in AOD treatment programs, as patients are 
frequently warned not to tackle smoking cessation during treatment for fear of jeopardizing 
their progress with recovery from addiction (Gil & Bennett, 2000; Hahn, Warnick, & 
Plemmons, 1999). In fact, only 8% of clients are told by counselors to quit tobacco use 
during AOD treatment (Joseph, Willenbring, Nugent, & Nelson, 2004). For adolescent 
patients who want to quit smoking during AOD treatment, NRTs may not be readily 
available, prescribable to minors, or without cost. As well, comorbid ADHD often goes 
unrecognized, particularly among girls (Biederman et al., 1999; Gaub & Carlson, 1997). 
Even if recognized, stimulant medications are considered off-limits for AOD-dependent 
youths with ADHD due to the addictive potential of stimulants. Untreated nicotine 
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withdrawal symptoms, AOD cravings, and impaired attention may decrease youths' chances 
of smoking cessation during treatment and increase their likelihood of treatment drop-out.
1.2. Smoking cessation and treatment response with comorbid ADHD
ADHD has high overlap with nicotine dependence, and may further challenge youths' ability 
to adhere to traditional treatment programs that are largely cognitive, behavioral, and social 
in nature. Given that ADHD is the most common psychiatric diagnosis of minors, the 
majority of individuals with AOD use disorders smoke (Friend & Pagano, 2005a, 2005b), 
and the smoke-free policies enforced at treatment facilities, the paucity of data on the impact 
of smoking cessation on AOD treatment response and in the presence of ADHD is 
surprising. Among adults, there is evidence that smoking cessation during AOD treatment is 
not associated with worse but improved drinking outcomes (Friend & Pagano, 2005a, 2005b, 
2007), although there is some argument to consider quitting smoking once AOD treatment is 
completed (Joseph et al., 2004). In fact, adults who continue smoking show worse drinking 
outcomes (Cooney, Cooney, Pilkey, Kranzler, & Oncken, 2003). Among youths, smoke-free 
policies in adolescent treatment facilities show no negative effects on retention rates 
(Callaghan et al., 2007). Initial evidence suggests no negative effects of smoking cessation 
among adolescents admitted into psychiatric hospitalization for axis 1 disorders including 
substance use (Brown et al., 2009; Myers & Kelly, 2006). It is unclear whether these 
findings extend to adolescents entering treatment for substance dependency and how ADHD 
complicates the picture. The handful of effectiveness studies of AOD treatment among youth 
with psychiatric comorbidity have been limited by insufficient sampling of girls to 
understand effects of ADHD inclusive of ADD without hyperactivity. In practice, ADHD is 
not an assessed condition that qualifies for dual-diagnosis treatment.
1.3. Purpose of this paper
The ability to focus, process higher-level cognition, and endure AOD cravings is a challenge 
for most AOD dependent patients in the initial months of AOD abstinence. Agitation and 
nicotine cravings from not being able to smoke during treatment can add to this common 
mental fog in early AOD recovery. Now add irritability, difficulty with peers, and impaired 
attention from untreated ADHD (Mrug, Hoza, Pelham, Gnagy, & Greiner, 2007; Pliszka, 
Greenhill, Crismon, et al., 2000) that is no longer medicated by AOD or nicotine use. The 
deck may be stacked against AOD dependent smokers with comorbid ADHD making 
progress in treatment. This paper aims to inform critical gaps between the mental health and 
addiction literatures by examining three research questions: 1) what are the clinical 
impairments associated with smoking among youths presenting for treatment?; 2) what are 
the characteristics of youths who successfully quit smoking during treatment?; and 3) what 
is the impact of smoking cessation on treatment response among smokers with and without 
ADHD? Understanding the interplay between smoking cessation, addiction, and ADHD can 
inform the integration and tailoring of treatment services to optimize patient health long-
term.
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2. Material and methods
2.1. Procedures
Data are drawn from a naturalistic, longitudinal study that enrolled a large, representative 
sample of AOD-dependent youths court-referred to treatment, selected for equal gender 
proportions to optimize generalization of study findings. Patients were recruited from a large 
adolescent residential treatment program in northeast Ohio. Inclusion criteria included: ages 
14–18 years, English speaking, stable address and telephone, met diagnostic criteria (APA, 
2000) for current AOD dependence, and medically stable. Exclusion criteria included: a 
major chronic health problem other than AOD disorders likely to require hospitalization, 
currently suicidal or homicidal, or expected incarceration in the subsequent 12 months. 
Participants were referred to AOD treatment from multiple sources, the most common of 
which were juvenile court (83%) and mental health professionals (65%). In the week before 
admission date, participants were sent an information packet with an invitation letter to 
participate in the study. Following admission, participants were approached to participate 
and given a brief description of the study. Participants were assured that their answers to 
study assessments would be kept confidential, and would not be shared with family 
members or treatment staff except when necessary to prevent harm to the participant or 
someone else. Eligible participants signed statements of informed assent with their parent/
legal guardian providing informed consent. Participants were paid $25 for completed 
assessments. All procedures of this study were approved by the University Hospitals Case 
Medical Center Institutional Review Board for human investigation, and a Certificate of 
Confidentiality from the National Institute on Alcohol Abuse and Alcoholism was obtained. 
The general aims, organization, and research design of longitudinal investigation can be read 
about in further detail elsewhere (Kelly, Pagano, Stout, & Johnson, 2011).
2.2. Setting
New Directions is a 24-hour monitored, intensive residential AOD treatment program lasting 
two months on average (M=2.2) that provides a range of evidenced-based therapies. Using 
the Drug and Alcohol Program Treatment Inventory (Swindle, Peterson, Paradise, & Moos, 
1995), the top five treatment modalities at the site are cognitive–behavioral (M = 11.0), 
psychodynamic (M = 11.0), therapeutic community (M = 10.0), family (M = 9.0), and 12-
step facilitated (M = 9.0), and are comparable to other adolescent AOD programs (Kelly & 
Urbanoski, 2012). Each week, clients spend approximately 20 hours in therapeutic activities 
and attend up to five 12-step meetings in the local community. Nicotine use is not allowed 
inside or outside the grounds of the facility. Nicotine patches are available upon client 
request, and clients are permitted to smoke when on pass or attending local 12-step 
meetings. Addiction medications and schedule II–IV medications (i.e. controlled substances) 
are not available to clients in adolescent AOD treatment.
2.3. Participants
A total of 482 adolescents were admitted into AOD treatment during the study enrollment 
period from February 2007 to August 2009. All youth with scheduled admission 
appointments as well as those unscheduled but occurring during regular weekday hours (8 
AM–6 PM), one weekday evening (5 PM–8 PM), and one weekend day (9 AM–5 PM), were 
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approached by research staff. All approached subjects (N = 211) met eligibility criteria and 
few (N = 16) refused to participate, who were equally represented by gender. There was a 
higher proportion of females among youth enrolled (52%) versus not enrolled (17%, p < .
0001), due to the study design's gender stratification. At the time of enrollment, all 
participants were between the ages of 14–18 and had approximately 7±3 days of sobriety. 
No participants were taking psychotropic medication or had a history of pathology that 
might have affected cognitive function.
Eighty-nine percent of the enrollment sample completed treatment, 6% were prematurely 
discharged against medical advice, and 5% were transferred to a higher-level medical 
facility – rates similar to other adolescent populations in AOD treatment (Kaminer, 
Burleson, & Goldberger, 2002; Wise, Cuffe, & Fischer, 2001). Eight discharge assessments 
were unable to be scheduled for 3 treatment completers, 3 premature discharges, and 2 
higher-level facility discharges. There were no significant intake differences between 
adolescents who were enrolled versus not enrolled but treated during the enrollment period 
in terms of intake characteristics and rates of treatment retention, as reported in detail 
elsewhere (Kelly et al., 2011). Participants without a discharge interview (4% of the 
enrollment sample) did not differ from participants with a discharge interview, as described 
in detail elsewhere (Lee, Pagano, Johnson, & Post, 2016).
2.4. Measures
Data were gathered via rater-administered, semi-structured interviews, medical chart review, 
biomarkers, clinician reports, and youth self-reports. Experienced research assistants 
(bachelor's to doctor of medicine degree) administered 60-minute interviews at intake within 
the initial week after admission, and in the week of treatment discharge (M=2.1 months 
between interviews). Interviewers received extensive training before beginning data 
collection and obtained National Institutes of Health's required certification on the protection 
of human subjects. Background, clinical, and AOD severity variables were assessed at 
intake; 12-step participation, outcomes, and nicotine variables were assessed at intake and 
discharge.
2.4.1. Background—Background variables included gender, race, ethnicity, age, parental 
marital status and education, and urbanicity of residence. Urbanicity of residence was 
assessed using the zip code approximation version of the census tract-based rural–urban 
commuting area codes (available at http://depts.washington.edu/uwruca/ruca-data.php).
2.4.2. Clinical—Five clinical indices included general health, ADHD, attempted suicide 
history, trauma experiences, and violent offenses. Using an item from the Youth Risk 
Behavior Survey (Kann, Brener, Warren, Collins, & Gioviono, 2002), participants rated their 
general health on a Likert scale from 1 (“poor”) to 5 (“excellent”). The rater-administered, 
semi-structured, MINI-International Neuropsychiatric Interview Plus (MINI-Plus; Arnaud et 
al., 2010; Sheehan et al., 1998) was used to assess DSM IV-TR AOD use disorders and 
ADHD, including age of disorder onset. Participants who endorsed ADHD criteria in the 
past 6 months were considered positive for current ADHD diagnosis. All participants 
received an initial diagnostic evaluation by the medical director board-certified in child 
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psychiatry as part of the admissions interview. Kappa statistics showed high agreement with 
clinician assessment of ADHD (κ = 0.92), and rates of ADHD (combined, n = 68; 
inattentive only, n=45; hyperactivity only, n=0) were comparable to other studies with AOD 
dependent minors (Kaminer et al., 2002; Waldron, Slesnick, Brody, Turner, & Peterson, 
2001). An item from the MINI-Plus was used to assess attempted suicide (“I have tried to 
commit suicide”). Trauma experiences were assessed with the four-item Traumatic 
Experiences scale adapted from the valid Massachusetts Youth Screening Inventory (Grisso 
& Barnum, 2000), which showed good internal consistency in the current sample (α = 0.86). 
Violent offenses, the most serious of crimes (Gottesman & Wile, 2011), were assessed with 
the self-report of delinquency (Elliott, Huizinga, & Menard, 1989). With reference to the 
past year, 10 items were rated from 0 (“never”) to 8 (“2–3 times a day”) and summed 
(range=0–80). Internal consistency of the violent offense score was high (α=.90). Intra-
correlations between clinical indices were non-significant except between traumatic 
experiences and violent offenses (r=.2, p < .01) and attempted suicide (r = .2, p < .01).
2.4.3. AOD severity—AOD severity indices were years of AOD use and readiness to 
change. Readiness to change was assessed using the University of Rhode Island Change 
Assessment scale (DiClemente, Schlundt, & Gemmell, 2004; Dozois, Westra, Collins, Fung, 
& Garry, 2004), which showed good internal consistency in the current sample (α=0.91). 
With reference to the past month, 32 items were rated from 1 (strong disagreement) to 5 
(strong agreement). Correlations between AOD severity indices were non-significant (rs = 
−0.1–0.2).
2.4.4. 12-step participation—Three indicators of 12-step participation included service, 
step-work, and meeting attendance. Service was assessed with the Service to Others in 
Sobriety (SOS) questionnaire (Pagano et al., 2010). With reference to the previous 90 days, 
12 items were rated from 1 (rarely) to 5 (always) and summed (range=12–60). The SOS 
demonstrated adequate psychometric properties in the current sample, including inter-
informant reliability (r= .5), internal consistency (α = .90), and convergent validity (rs = 
−0.3–0.3; Pagano et al., 2013). Step-work was assessed with the General Alcoholics 
Anonymous (AA) Tools of Recovery (GAATOR) scale (Greenfield & Tonigan, 2013), a 24-
item self-report of the practice of the 12 steps in daily living. With reference to the past 90 
days, each item was rated on a Likert scale from 0 (“definitely false”) to 3 (“definitely true”) 
and summed (range = 0–72). The GAATOR demonstrated good internal reliability with the 
current sample (α > .80). Meeting attendance was assessed with the single item, “How many 
12-step meetings have you attended in the past 90 days?” Intake correlations between 12-
step indicators were low to moderate (rs = 0.2–0.4, p < .01).
2.4.5. Outcomes—Three treatment outcomes shown to predict relapse were assessed, 
including AOD use, AOD cravings, and global functioning (Brown, Vik, Patterson, Grant, & 
Schuckit, 1995; MacKillop et al., 2010). AOD use was assessed using the Time Line Follow 
Back (TLFB) interview (Donohue et al., 2004), a calendar-grid method for tracking daily 
use of alcohol and eight types of drugs (amphetamines, hallucinogens, cocaine, marijuana, 
inhalants, sedatives, narcotics, steroids) over an assessment period. To calculate the 
percentage of days drinking or using each drug type, the number of days a subject reported 
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use of each substance was divided by the number of days in the time period multiplied by 
100. Percentage of days abstinent (PDA) was calculated as the number of days a subject was 
abstinent from AOD divided by the number of days in the time period multiplied by 100. 
The Adolescent Obsessive Compulsive Drinking (AOCD) scale (Deas, Roberts, Randall, & 
Anton, 2002) was used to assess AOD cravings and obsessive thoughts. With reference to 
the past week, 14-items were rated on a Likert scale from 0 (“none/never”) to 5 (“always/
extreme”) and summed (range = 0–72). The AOCD scale showed good internal consistency 
in the current sample (α = .85). Participants' worst global functioning at home, school, and 
with peers was measured with the clinician-rated Children's Global Assessment Scale (range 
= 0–100; Rey, Starling, Wever, Dossetor, & Plapp, 1995). There were low correlations 
between outcome variables at intake and discharge (rs = −0.1–0.1, ns).
2.4.6. Nicotine use—Participants' nicotine consumption was primarily cigarettes (no cigar 
use), and two subjects reported chewing tobacco once. Therefore, nicotine variables 
included: number of days smoked in the current period, number of cigarettes per day, and 
time to first cigarette upon awakening on last smoking day. Daily consumption of nicotine 
products (cigarettes, tobacco chew, cigars) was collected using the TLFB nicotine 
assessment. Nicotine users were identified using nicotine consumption thresholds 
recommended by others conducting research with AOD populations who smoke (Center for 
Substance Abuse Treatment, 2005; Naqvi, Rudrauf, Damasio, & Bechara, 2007), 
participants who smoked at least 10 cigarettes per month and more than five cigarettes per 
smoking day were considered to smoke. Very few participants smoked at least 1 cigarette but 
below this threshold at baseline (N=5) or during the 10-week treatment period (N=0). 
Nicotine replacement therapies prescribed to participants during AOD treatment were 
recorded from medical chart records. Nicotine use variables were moderately correlated at 
intake and discharge (rs= −0.3–0.3, p < .01).
2.4.7. Statistical analysis plan—Statistical analyses were performed with SAS Version 
9.2 (SAS Institute Inc., 2008). Fisher's Exact Tests for binary variables or Kruskal–Wallis 
chi-square tests for continuous variables were performed to evaluate differences between 
groups. Distributions of variables were examined for normality. The negatively skewed PDA 
variable received an arcsine transformation. Following descriptive analyses, we first 
evaluated intake characteristics associated with smoking. We then used logistic regression 
analysis to identify intake characteristics that distinguished participants who continued to 
smoke during the 10-week treatment period. Finally, hierarchical linear regression analyses 
were performed to evaluate the impact of smoking cessation, ADHD, and their interaction 
term on 12-step participation and outcomes collected at discharge. Intake covariates 
associated with either 12-step participation or outcomes in prior research such as antisocial 
behaviors (Biederman et al., 2006; Pagano, Zemore, Onder, & Stout, 2009) were controlled 
for in analytic models, including: background, clinical, AOD severity, number of days 
smoking, and the dependent variable at intake. Preliminary analyses suggested that linear 
modeling was adequate. Examination of the correlation matrix for independent variables in 
analytic models found no correlation to exceed 0.3 and collinearity diagnostics indicated no 
problems. The family-wise error rate for the two sets of treatment response indicators was 
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set at p < .05 (two-tailed). For the purposes of interpretation, Cohen (1988) considers r = 0.1 
“small,” r = 0.3 “medium,” and r = 0.5 “large.”
3. Results
3.1. Intake profile
Approximately half the sample was male (48%; quota sample), from single parent 
households (50%), and resided in rural/small town settings (53%). The mean age was 16 
years (SD = 1.1). Thirty percent were Black and 8% were Hispanic. Large majorities had a 
parent with a high-school education or less (74%) and were in good health (68%). Thirty-
five percent met current criteria for combination ADHD and 23% met current criteria for 
ADD (inattentive only); the mean age of disorder onset was 5.7 years (SD=1.3). Thirty-one 
percent had 2 or more lifetime traumatic experiences (M = 1.7, SD= 1.5) and 24% had a 
history of attempted suicide. The majority entered treatment with marijuana dependence 
(92%), comorbid alcohol dependence (60%), and elevated AOD cravings (M = 33.5, SD = 
11.3). The most prevalent drug dependence substances comorbid with marijuana dependence 
were narcotics (36%), hallucinogens (35%), and stimulants (30%). Participants were, on 
average, in the pre-contemplative stage of change (M=11.0, SD=2.5) and used AOD at least 
half (60%) of the past month.
Two out of three youths (67%) reported smoking on 10+days in the month prior to treatment 
(M=21.4 days, SD=9.4) and 5+ cigarettes on smoking days (M = 12.5 cigarettes, SD = 9.0). 
The average time to first cigarette was within an hour upon awakening (M=53.6 minutes, SD 
= 81.1). Smoking was associated with higher trauma (X2 = 4.6, p < .05), attempted suicide 
(X2 = 5.3, p < .05), and ADHD (X2 = 5.5, p < .05; Table 1).
3.2. Discharge profile
After approximately 2 months of treatment (M=10.2 weeks, SD = 2.1), the smoking sample 
overall (N = 149) showed improvements in 12-step participation (step-work: t =−7.7, p < .
001; service: t =−8.2, p < .001; meeting attendance: t = −14.2, p < .001), global functioning 
(t = −25.4, p < .001), AOD cravings (t =25.9, p < .001), and PDA (t = 25.9, p < .001), 
although half (50%) used AOD at least once. Half (50%) continued to smoke and half (50%) 
did not smoke on any day during the 10-week treatment period. While continuing smokers 
smoked on fewer days (M=15.0, SD=8.9; F=4.1, p < .01), the number of cigarettes they 
smoked on smoking days (M=10.6, SD=9.2) and time to first cigarette (M=70.1, SD=120) 
were similar to pre-treatment levels. Youths who continued to smoke versus quit smoking 
were similar at intake in terms of background characteristics, AOD dependence substances, 
and nicotine use (M = 21.2 vs M = 22.2 days smoking, ns; M = 12.1 vs M=12.2 
cigarettes/per smoking day, ns; M=54.3 vs M=55.1 minutes to first cigarette, ns). Few 
youths who continued to smoke or quit smoking received nicotine patches during treatment 
(4% vs 6%, ns).
3.3. Predictors of smoking cessation
Most intake characteristics were not associated with smoking cessation (Table 2). However, 
ADHD significantly increased the likelihood of continuing to smoke (OR=4.1, p < .0001). 
Pagano et al. Page 8
J Subst Abuse Treat. Author manuscript; available in PMC 2016 November 17.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Post-hoc analyses were performed to evaluate that the extent to continuing smokers with 
ADHD was similar at baseline from quitters with and without ADHD, which found no 
differences.
3.4. Impact of smoking cessation on treatment response with ADHD comorbidity
Table 3 shows treatment response variables among youths who continued to smoke versus 
quit smoking with and without ADHD. Results of hierarchical linear regression analyses 
found no significant main effects of smoking cessation on treatment duration, 12-step 
participation, and outcomes with one exception. A significant main effect of smoking 
cessation on AOD cravings (F = 9.6, p < .01) indicated that continuing smokers were 
discharged with higher levels of AOD cravings (M = 10.6) than quitters (M = 5.6). ADHD 
was associated with lower step-work (M = 68.9 vs M = 75.0, F = 10.3, p < .01), service (M = 
29.6 vs M = 33.1, F = 4.0, p < .05), and functioning (M = 57.4 vs M = 59.3, F = 3.8, p < .
05). However, a significant interaction between smoking cessation X ADHD was found for 
service (F = 3.9, p < .05) and step-work (F = 8.9, p < .01). Step-work was highest among 
continuing smokers without ADHD, followed by those who quit smoking (with and without 
ADHD), and lowest among continuing smokers with ADHD. Continuing smokers without 
ADHD and youths who quit smoking (with and without ADHD) had similar levels of 
service which were significantly higher than continuing smokers with ADHD.
4. Discussion
4.1. Impact of smoking cessation on treatment response
The treatment of nicotine addiction during AOD treatment has been largely avoided without 
a sound scientific rationale. This study suggests that AOD treatment outcomes are better if 
alcohol, drug, and nicotine addictions are treated simultaneously. In this sample of substance 
dependent youths, smoking cessation was not associated with worse treatment outcomes but 
better prognosis in terms of lower AOD cravings. In contrast, continuing to smoke was 
associated with more severe AOD cravings, which has been shown to increase the risk of 
AOD relapse post-treatment (MacKillop et al., 2010). If the conditional appetite 
motivational theory of AOD cravings (Rohsenow & Monte, 1999) applies across substances, 
lighting up a cigarette may trigger cravings to smoke other substances like nicotine, which 
warrants future research. These findings extend prior work with treatment-seeking adults 
(Friend & Pagano, 2005a, 2005b), and are consistent with community studies with 
adolescents that show smoking associated with problems with AOD use even at low levels of 
smoking (Cavazos-Rehg, Krauss, Spitznagel, Grucza, & Bierut, 2014). While continuing 
smokers had fewer days of smoking, this decline is likely due to being confined to a smoke-
free, 24-hour monitored residential program, given their nicotine consumption patterns were 
similar on the days they did smoke. Study findings suggest that clean air policies in AOD 
treatment settings do not interfere with youth progress during AOD treatment and enhance 
smoking cessation efforts.
4.2. Impact of smoking cessation on treatment response with ADHD comorbidity
This study highlights a common problem many adolescents face upon entry into AOD 
residential treatment: they cannot smoke and they cannot receive front-line, stimulant 
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medication for ADHD comorbidity. Is smoking cessation beneficial for these youths with 
comorbid ADHD? Results appear more complicated for ADHD patients who smoke. ADHD 
clearly decreased the chances of smoking cessation and was associated with worse 
functioning, which may be due to lower performance in treatment classrooms, poor 
executive functioning, and impulsive symptoms associated with this disorder. Untreated 
ADHD may pose a barrier to participating and benefiting from the 12-step program. While 
ADHD did not interfere with meeting attendance, it was associated with less step-work and 
service participation. ADHD symptoms of impaired attention and lack of task persistence 
may hinder step-work whereas irritability, aggression, and low social skills (Mrug et al., 
2007; Pliszka et al., 2000) may interfere with getting along with peers in mutual-help 
activities. This is unfortunate given that AA provides a natural, social platform for finding 
sober peers and support for a chronic, lifelong disease.
Unless channeled in action-oriented programmatic activities, frustration tolerance may be 
too low in early recovery for many ADHD patients to endure symptoms without smoking. 
Smoking before or after meetings in the local community may also limit opportunity and 
invitations to help set up or put away chairs, greet newcomers, or make coffee – natural, 
low-intensity tasks that facilitate getting to know and be known by AA members. ADHD 
patients who quit smoking participated in service and step-work at comparable levels to 
youths without ADHD who quit smoking, whereas continuing smokers with ADHD had 
significantly lower levels in these activities. We speculate that becoming active in service 
may distract quitters from symptoms of nicotine withdrawal, provide an outlet for ADHD, 
and fan motivation to continue with step-work. Getting active in service may be particularly 
useful for smoking cessation with or without ADHD comorbidity as a mild form of exercise, 
which has some efficacy in reducing adolescent nicotine use and increasing focus 
(Escobedo, Marcus, Holtzman, & Giovino, 1993; Thorlindsson, Vilhjalmsson, & 
Valgeirsson, 1990).
4.3. Limitations and strengths
Some limitations of our study merit attention. First, nicotine use variables were self-reported 
and not validated with biochemical testing. However, prior studies using biochemical 
markers show low rates of false reporting (Joseph et al., 2004). Related, because nicotine use 
but not withdrawal symptomology was measured, future research is warranted and underway 
(R01 CA190130) to explore the observed escalation of nicotine dependence among 
adolescents (Kleinjan et al., 2012) and influence on quit attempts and outcomes. Second, 
sample sizes were too small to examine differential outcomes by ADHD type and receipt of 
nicotine patches. Third, participants were forced to not smoke on the premises of the 
residential treatment facility and results may not generalize to populations seeking help to 
quit smoking. Lastly, a randomized control trial is needed to determine the causal 
relationships between smoking cessation, ADHD, and adolescent treatment response. 
However, intake characteristics including severity of nicotine use, treatment duration, and 
meeting attendance were similar between youths who quit smoking versus continued to 
smoke with and without ADHD, suggesting that differences between groups cannot be 
explained by intake characteristics, an equal dose of formal treatment, and similar 
opportunity to smoke at local meetings. Strengths of this study include: closely spaced 
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longitudinal data on AOD and nicotine use; robust analyses that control for potential 
confounding variables such as antisocial behaviors; and a representative sample of juveniles 
with substance dependency (52% females, 30% minority). The large sample and balanced 
smoking cessation groups (74 smokers versus 75 quitters) were ideal for maximizing power 
(>80% available) to detect at least moderate differences between groups. The environment in 
which subjects were studied (e.g., 24-hour monitored care for 10 consecutive weeks) 
provided a natural laboratory to study adolescent behavior independent of familial or deviant 
peer-group influences.
4.4. Clinical implications
Smoking is associated with increased clinical vulnerabilities including ADHD and more 
trauma. Quitting smoking did not adversely affect AOD outcomes and was associated with 
better prognosis of lowered AOD cravings for youths with and without ADHD. Adolescent 
patients who smoke and those with ADHD in particular should be routinely offered NRT 
and warned about the link between tobacco use and higher AOD cravings. Low-cost, non-
pharmaceutical approaches like service may enhance quit attempts during treatment, aid 
with attention deficit, and support smoking cessation long-term. Facilitation of youth 
engagement in service activities may allow more ADHD smokers to benefit. Future research 
is recommended to determine which ADHD symptoms are aggravated in response to 
smoking cessation and respond to 12-step involvement.
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Table 1
Intake profile.
Total Smoking Not smoking
Intake variable 195 (100%) 149 (76%) 46 (24%)
Background
 Male (%) 93 (48%) 71 (48%) 22 (48%)
 Minority (%) 59 (30%) 46 (31%) 13 (28%)
 Hispanic (%) 15 (8%) 13 (9%) 2 (4%)
 Age (M, SD) 16.2 (1.1) 16.3 (1.1) 15.3 (1.0)
 Single parent (%) 98 (50%) 75 (50%) 23 (50%)
 Parent education <BA+ (%) 144 (74%) 105 (70%) 39 (84%)
 Rural/Small town (%) 103 (53%) 79 (53%) 24 (52%)
Clinical
 Good health (%) 133 (68%) 101 (68%) 32 (70%)
 ADHD (%) 113 (58%) 97 (65%)* 16 (35%)
 Suicide attempt history (%) 46 (24%) 40 (27%)* 6 (13%)
 Trauma experiences (m, SD) 1.7 (1.5) 1.9 (1.4)* 1.2 (1.4)
 Violent offenses (m, SD) 1.7 (1.6) 1.8 (1.7) 1.5 (1.3)
AOD severity
 Readiness for change (M, SD) 11.0 (2.5) 10.9 (2.5) 11.2 (2.5)
 Years of use (M, SD) 3.4 (1.5) 3.4 (1.5) 3.3 (1.6)
12-step
 Meeting attendance (M, SD) 2.8 (1.8) 5.3 (1.7) 4.7 (1.8)
 Step-work (M, SD) 63.5 (13.7) 62.0 (14.1) 65.0 (12.1)
 Service (M, SD) 26.0 (10.4) 25.8 (10.1) 26.2 (10.5)
Outcomes at intake
 Percent days using (M, SD) 0.6 (0.3) 0.6 (0.3) 0.5 (0.2)
 AOD cravings (M, SD) 33.5 (11.3) 33.8 (11.4) 32.6 (11.1)
 Global functioning (M, SD) 49.5 (2.7) 49.6 (2.7) 49.2 (2.3)
Note: ADHD = attention deficit hyperactivity disorder (all types); minority = black; AOD = alcohol and other drugs.
*
p < .05.
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Table 2
Predictors of Smoking Cessation.
Intake variable Estimate(se) X 2 p OR 95% CI
Background
 Male 0.06 (0.57) 0.01 0.91 0.66 0.29, 1.50
 Black 0.47 (0.51) 0.83 0.36 0.66 0.27, 1.67
 Hispanic 0.89 (0.78) 1.29 0.25 0.29 0.07, 1.22
 Age 0.08 (0.18) 0.17 0.67 0.95 0.66, 1.38
 Single parent 0.55 (0.45) 1.45 0.22 0.57 0.26, 1.28
 Parent education 0.08 (0.48) 0.02 0.86 1.03 0.75, 1.44
 Rural/Small town 0.87 (0.58) 2.23 0.17 0.42 0.18, 1.03
Clinical
 Health −0.08 (0.51) 0.02 0.87 0.92 0.39, 2.19
 ADHD 2.09 (0.47) 19.33 **** 4.12 3.00, 6.01
 Suicide attempt history 0.37 (0.47) 0.60 0.43 0.64 0.26, 1.55
 Trauma experiences −0.22 (0.15) 2.15 0.14 1.20 0.91, 1.60
 Violent offenses 0.07 (0.13) 0.25 0.61 0.78 0.59, 1.05
AOD severity
 Readiness for change 0.15 (0.10) 2.08 0.14 0.87 0.54, 1.41
 Years of use 0.34 (0.62) 0.30 0.58 0.81 0.26, 2.52
12-step
 Meeting attendance −0.03 (0.02) 0.03 0.84 0.87 0.54, 1.41
 Step-work −0.03 (0.02) 1.86 0.17 0.87 0.54, 1.41
 Service 0.01 (0.02) 0.24 0.62 0.91 0.56, 1.45
Outcomes at intake
 Percent days using 0.66 (0.79) 0.70 0.39 0.87 0.54, 1.41
 AOD cravings 0.01 (0.01) 0.11 0.73 0.87 0.54, 1.41
 Global functioning 0.19 (0.11) 1.56 0.21 0.91 0.56, 1.45
Nicotine use
 #days smoking −0.02 (0.02) 0.46 0.49 1.01 0.98, 1.06
Note: ADHD = attention deficit/hyperactivity disorder (all types); AOD = alcohol and other drugs; OR= odds ratio; CI= confidence interval.
****
p < .0001.
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Table 3
Impact of smoking cessation on treatment response with ADHD comorbidity.
Continuing smoking Smoking cessation
74 (50%) 75 (50%)
Total No ADHD ADHD no ADHD ADHD
Treatment response variable 149 (100%) 13 (18%) 61 (82%) 39 (52%) 36 (48%)
Treatment duration (weeks) 10.3 (2.4) 10.7 (2.5) 9.9 (2.8) 10.4 (2.0) 10.6 (1.9)
12-step
 Meeting attendance 25.9 (4.0) 26.4 (5.1) 23.0 (3.4) 27.5 (3.9) 25.5 (4.3)
 Step-work 72.5 (11.3) 77.5 (3.3)a 66.5 (2.5)c 70.5 (2.7)b 70.5 (2.9)b
 Service 35.4 (8.8) 34.9 (2.5)a 26.9 (1.6)b 32.4 (1.9)a 31.6 (2.1)a
Outcomes at discharge 1
 Percent days using 0.2 (0.3) 0.2 (0.3) 0.2 (0.4) 0.2 (0.4) 0.2 (0.3)
 AOD cravings 9.4 (8.8) 10.7 (2.9)a 10.6 (1.8)a 4.0 (2.1)b 6.1 (2.3)b
 Global functioning 61.3 (6.0) 59.9 (1.6) 56.6 (1.1) 59.1 (1.3) 58.6 (1.4)
Note: groups sharing the same are letter are not significantly different; adjusted for background, clinical, alcohol/drug severity, nicotine use, and 
intake assessment of outcome; ADHD=attention deficit/hyperactivity disorder (all types).
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